Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Net Income (2019 - 2025)

Historic Net Income for Madrigal Pharmaceuticals (MDGL) over the last 13 years, with Q3 2025 value amounting to -$111.1 million.

  • Madrigal Pharmaceuticals' Net Income fell 388.35% to -$111.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$286.0 million, marking a year-over-year increase of 4485.68%. This contributed to the annual value of -$465.9 million for FY2024, which is 2469.34% down from last year.
  • Latest data reveals that Madrigal Pharmaceuticals reported Net Income of -$111.1 million as of Q3 2025, which was down 388.35% from -$42.2 million recorded in Q2 2025.
  • In the past 5 years, Madrigal Pharmaceuticals' Net Income ranged from a high of -$42.2 million in Q2 2025 and a low of -$152.0 million during Q2 2024
  • In the last 5 years, Madrigal Pharmaceuticals' Net Income had a median value of -$76.9 million in 2023 and averaged -$84.4 million.
  • Its Net Income has fluctuated over the past 5 years, first crashed by 9187.08% in 2024, then skyrocketed by 7220.59% in 2025.
  • Over the past 5 years, Madrigal Pharmaceuticals' Net Income (Quarter) stood at -$64.5 million in 2021, then tumbled by 33.08% to -$85.9 million in 2022, then crashed by 30.6% to -$112.2 million in 2023, then soared by 47.04% to -$59.4 million in 2024, then crashed by 87.02% to -$111.1 million in 2025.
  • Its Net Income was -$111.1 million in Q3 2025, compared to -$42.2 million in Q2 2025 and -$73.2 million in Q1 2025.